ALG 1001

Drug Profile

ALG 1001

Alternative Names: ALG-1001; Integrin Peptide Therapy; Luminate

Latest Information Update: 29 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allegro Ophthalmics
  • Class Anti-inflammatories; Eye disorder therapies; Oligopeptides
  • Mechanism of Action Integrin alpha 5 beta 1 modulators; Integrin alpha2beta1 modulators; Integrin alphaVbeta3 modulators; Integrin alphaVbeta5 modulators; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Diabetic retinopathy; Retinal disorders; Wet age-related macular degeneration

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Diabetic-macular-oedema in Mexico (Intravitreous, Injection)
  • 09 Aug 2017 Efficacy and adverse events data from the phase IIb DEL MAR trial in Diabetic macular oedema released by Allegro Opthalmics
  • 25 Jul 2017 Allegro Ophthalmics plans multiple phase III trials in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top